Researchers at Fudan University Shanghai Cancer Center have identified a novel blood biomarker capable of forecasting patient response to immunotherapy in triple-negative breast cancer (TNBC). This aggressive subtype typically shows heterogeneous treatment outcomes; the new test facilitates precision medicine by stratifying candidates poised to benefit most from immune checkpoint inhibitors, potentially enhancing survival rates.